Explore › Intervention › Oral anticoagulation
Intervention

Oral anticoagulation

Also known as: Oral anticoagulation for low-risk atrial fibrillation (CHADS2/CHA2DS2-VASc score 0)
3 findings 1 paper 3 related entities View in graph →

Related entities

conditions
non-valvular atrial fibrillation1
outcomes
Rate of speech1
studys
PMC55643941

Findings (27)

None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →
None
adverse

Among atrial fibrillation patients under 60 with no structural heart disease and stroke risk scores of zero, approximately one in four (23.3-26.6%) were prescribed oral anticoagulants despite guidelin

Effect: adverse; 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescribed oral anticoagulants

Size: 23.3% (CHADS2 cohort) and 26.6% (CHA2DS2-VASc cohort) prescr
PMC5564394
Finding details → · Paper → · Graph →

Papers (1)